Cited by 230Psychedelics and Drug StudiesTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Open access

Roseman, Leor, Demetriou, Lysia, Wall, Matthew B., Nutt, David J., Carhart-Harris, Robin L.·2018·Neuropharmacology

DOI 10.1016/j.neuropharm.2017.12.041

Open this paper in CoChat — free account Open PDF

Abstract

Recent evidence indicates that psilocybin with psychological support may be effective for treating depression. Some studies have found that patients with depression show heightened amygdala responses to fearful faces and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hypothesised that amygdala responses to emotional faces would be altered post-treatment with psilocybin. In this open-label study, 20 individuals diagnosed with moderate to severe, treatment-resistant depression, underwent two separate dosing sessions with psilocybin. Psychological support was provided before, during and after these sessions and 19 completed fMRI scans one week prior to the first session and one day after the second and last. Neutral, fearful and happy faces were presented in the scanner and analyses focused on the amygdala. Group results revealed rapid and enduring improvements in depressive symptoms post psilocybin. Increased responses to fearful and happy faces were observed in the right amygdala post-treatment, and right amygdala increases to fearful versus neutral faces were predictive of clinical improvements at 1-week. Psilocybin with psychological support was associated with increased amygdala responses to emotional stimuli, an opposite effect to previous findings with SSRIs. This suggests fundamental differences in these treatments' therapeutic actions, with SSRIs mitigating negative emotions and psilocybin allowing patients to confront and work through them. Based on the present results, we propose that psilocybin with psychological support is a treatment approach that potentially revives emotional responsiveness in depression, enabling patients to reconnect with their emotions. TRIAL REGISTRATION: ISRCTN, number ISRCTN14426797. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.12.041

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages
Cox, R. W. (1996) · Computers and Biomedical Research · doi:10.1006/cbmr.1996.0014 · Cited by 10,913
Cortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910
Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.10.018 · Cited by 7,429
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 3×
“, 2015), end of life anxiety (Gasser et al., 2014a; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), obsessive compulsive disorder (Moreno et al.”
From circuits to behaviour in the amygdala
Janak, P. H., & Tye, K. M. (2015) · Nature · doi:10.1038/nature14188 · Cited by 2,011 · cited 1×
“The amygdala is a complex subcortical structure that is sensitive to emotional stimuli (Janak and Tye, 2015; Sergerie et al., 2008).”

Show all 57 references

Sorted by citations

Items 101–200 of 229

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review
Kuburi, S., Passa, A.-M. D., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K., Rizvi, S. J., Demchenko, I., & Bhat, V. (2022) · Chronic Stress · doi:10.1177/24705470221115342 · Cited by 14
Extrapharmacological Safety Topics in Psychedelic-Assisted Psychotherapy
Calder, A. E., & Hasler, G. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1031 · Cited by 13
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 12
A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents
Bogadi, M., & Kaštelan, S. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.528 · Cited by 13
Effect of a single psilocybin treatment on Fos protein expression in male rat brain
Funk, D. R., Araujo, J. A., Slassi, M., Lanthier, J., Atkinson, J., Feng, D., Lau, W., Lê, A., & Higgins, G. A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.01.001 · Cited by 15
Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy
Schmid, Y., & Bershad, A. K. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.001 · Cited by 15
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“The amygdala has been found to show greater responsiveness to emotional faces 1 day after psilocybin consumption and greater responsiveness to fearful versus neutral faces was related to improved depressive symptoms 1 week post-intervention [36].”
The phenomenology of psilocybin: transformative insights for research and clinical practice
Metastasio, A., Prevete, E., Venturini, S., Garofalo, A., Cecconello, B., Pisapia, N. D., & Corazza, O. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1455902 · Cited by 14
Classic psychedelics: the special role of the visual system
Császár-Nagy, N., Kapócs, G., & Bókkon, I. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0092 · Cited by 12
A continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
Psilocybin Conspectus: Status, Production Methods, and Considerations
Plotnik, L., Gibbs, G., & Graham, T. (2021) · International journal of medicinal mushrooms · doi:10.1615/intjmedmushrooms.2021041921 · Cited by 11
FMRI study of implicit emotional face processing in patients with MDD with melancholic subtype
Kustubayeva, A., Eliassen, J. C., Matthews, G., & Nelson, E. B. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1029789 · Cited by 10
A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?
Császár-Nagy, N., Bob, P., & Bókkon, I. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2105148 · Cited by 10
In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
Jones, N., Wagner, L., Pellitteri-Hahn, M. C., Scarlett, C. O., & Wenthur, C. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1303365 · Cited by 12
Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017
Anthony, J., WINSTOCK, A. R., Ferris, J., & Nutt, D. (2020) · Drug Science Policy and Law · doi:10.1177/2050324520942345 · Cited by 10
Self-citation
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 9
Regulatory Role of PFC Corticotropin-Releasing Factor System in Stress-Associated Depression Disorders: A Systematic Review
Alizamini, M. M., Fattahi, M., Sayehmiri, F., Haghparast, A., & Liang, J. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01289-2 · Cited by 9
Tripping to Cope: Coping Strategies and Use of Hallucinogens during the COVID-19 Pandemic in Three Cultural Contexts
Oña, G., Révész, D., Kohek, M., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2022) · Psychoactives · doi:10.3390/psychoactives1010003 · Cited by 10
Classic psychedelics do not affect T cell and monocyte immune responses
Rudin, D., Areesanan, A., Liechti, M. E., & Gründemann, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1042440 · Cited by 11
Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises
Harding, R., Singer, N., Wall, M. B., Hendler, T., Erritzøe, D., Nutt, D., Carhart-Harris, R. L., & Roseman, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03035-8 · Cited by 11
Self-citation
Cyberdelics: Virtual reality hallucinations modulate cognitive-affective processes
Brizzi, G., Pupillo, C., Rastelli, C., Greco, A., Bernardelli, L., Natale, A. F. D., Pizzoli, S. F. M., Sajno, E., Frisone, F., Lernia, D. D., et al. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499459 · Cited by 11
Role of the amygdala and possible biomarkers in psychiatric disorders
Flores, G., Reyes-Lizaola, S., Aguilar‐Hernández, L., Gil‐Velazco, A., Tendilla‐Beltrán, H., & Morales‐Medina, J. C. (2024) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100032 · Cited by 12
Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals
Armand, S., Larsen, K., Madsen, M. K., Ozenne, B., Preller, K. H., Knudsen, G. M., Stenbæk, D. S., & Fisher, P. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103934 · Cited by 7
Stroboscopically induced visual hallucinations: historical, phenomenological, and neurobiological perspectives
Hewitt, T., Amaya, I. A., Beauté, R., Seth, A. K., Schmidt, T. T., & Schwartzman, D. J. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niaf020 · Cited by 8
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 7
Psychedelics – Re-opening the doors of perception
Heal, D. J., Henningfield, J. E., Frenguelli, B. G., Nutt, D., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.024 · Cited by 7
Self-citation
The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review
Ramos, L., & Vicente, S. (2024) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2024.2363343 · Cited by 6
What fMRI studies say about the nature of the psychedelic effect: a scoping review
Beneš, M., Páleníček, T., & Horáček, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1606798 · Cited by 7
Brain changes associated with depression treatment: a meta-analysis
Perez, G. M., Rosenberg, B. M., Xu, W., & Oathes, D. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103874 · Cited by 6
Neurobiological substrates of altered states of consciousness induced by high ventilation breathwork accompanied by music
Kartar, A. A., Horinouchi, T., Örzsik, B., Anderson, B., Hall, L., Bailey, D., Samuel, S., Beltran, N., Bouyagoub, S., Racey, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329411 · Cited by 8
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review
Viljoen, G., Walter, H., Bendau, A., Koslowski, M., & Betzler, F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389581 · Cited by 8
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain
Levin, A. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303599 · Cited by 5
The emotional architecture of the psychedelic brain
Moujaes, F., Rieser, N. M., Belinger, L., Herdener, M., Zahid, Z., & Preller, K. H. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.006 · Cited by 5
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
Pasculli, G., Busan, P., Jackson, E. S., Alm, P. A., Gregorio, D. D., Maguire, G. A., Goodwin, G. M., Gobbi, G., Erritzøe, D., & Carhart-Harris, R. L. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1402549 · Cited by 6
Self-citation
Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects
Rieser, N. M., Schmidt, T. T., & Preller, K. H. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_507 · Cited by 6
Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology
Moroz, M., & Carhart-Harris, R. L. (2018) · doi:10.1109/var4good.2018.8576882 · Cited by 6
Self-citation
1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
Vilca-Melendez, S., Uthaug, M. V., & Griffin, J. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742856 · Cited by 5
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review
Wong, S., Jones, B. D. M., Thiyagarajah, M. T., Sabbah, S. G., Thompson, C. W., Solmi, M., Umer, M., Zrenner, C., Voineskos, D., Rosenblat, J. D., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251384513 · Cited by 4
Therapeutic-Like Context and Relational Support During Psychedelic Use Moderate Links Among Stress, Challenging Experiences, and Psychological Outcomes
Cherniak, A. D., Granqvist, P., Mikulincer, M., & Wolff, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644857 · Cited by 4
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 4
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives – A Computational Study
(2022) · Letters in Applied NanoBioScience · doi:10.33263/lianbs124.105 · Cited by 4
Psychedelic therapies and belief change: are there risks of epistemic harm or epistemic injustice?
Zeller, M. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2362284 · Cited by 4
Psychedelics and the future evolution of humanity
Winkelman, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00464 · Cited by 4
Role of the rostral anterior cingulate cortex in emotion processing in Treatment Resistant Depression
Barreiros, A. R., Breukelaar, I. A., Mayur, P. M., Andepalli, J., Tomimatsu, Y., Funayama, K., Foster, S., Harris, A. W. F., & Korgaonkar, M. S. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03600-3 · Cited by 4
Cognitive control as a transdiagnostic mechanism of action in psychedelic effects
Sayalı, C., Truesdale, A., Rosen, D. S., & Barrett, F. S. (2025) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-025-01362-5 · Cited by 3
Negative affective bias in depression following treatment with psilocybin or escitalopram – a secondary analysis from a randomized trial
Martens, M., Cunha, B. G., Erritzøe, D., Nutt, D., Carhart-Harris, R. L., & Harmer, C. J. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03693-w · Cited by 5
Self-citation
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Kaczmarek, E. S., Rodrigues, N. B., Chisamore, N., Doyle, Z., Meshkat, S., Blainey, M. G., Brudner, R. M., Ali, S., Teopiz, K. M., McIntyre, R. S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121385 · Cited by 3
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 4
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
Self-citation
Psychedelic visuals in context
Swanson, L. R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0006 · Cited by 3
Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics
Wall, M. B., Harding, R., Ertl, N., Barba, T., Zafar, R. R., Sweeney, M., Nutt, D., Rabiner, E. A., & Erritzøe, D. (2024) · Neuroscience Insights · doi:10.1177/26331055241286518 · Cited by 3
Self-citation
Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal
Sabbah, S. G., Li, S., Wong, S., Le, G. H., Badulescu, S., Hawco, C. S., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120335 · Cited by 4
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 3
Mechanisms of integration in psychedelic-assisted therapy
Coverdale, N. S., & Cook, D. J. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0014 · Cited by 4
Neurotransmitter modulation of human facial emotion recognition
Vlazaki, M., Harmer, C. J., Cowen, P. J., & Pulcu, E. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338225 · Cited by 4
HUBUNGAN RELIGIUSITAS DAN REGULASI EMOSI SISWA SEKOLAH DASAR
Angelia, M., Tiatri, S., & Heng, P. H. (2020) · Jurnal Muara Ilmu Sosial Humaniora dan Seni · doi:10.24912/jmishumsen.v4i2.8252.2020 · Cited by 3
Classic psychedelics: past uses, present trends, future possibilitiesPreprint
Safron, A., & Johnson, M. W. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/eys2j · Cited by 3
Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewPreprint
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574146 · Cited by 3
The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal
Fernández‐Borkel, T., Borkel, L. F., Rojas‐Hernández, J., Hernández‐Álvarez, E., Hernández, D. J. Q., Ponti, L. G., & Henríquez‐Hernández, L. A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00445 · Cited by 3
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review
Ramarushton, B., Blumenthal, H., Ryals, A. J., Boals, A., & Thompson, L. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0009 · Cited by 3
Managing Psychological Challenges in the Subacute (“Afterglow”) Window of Psychedelic Drug Effects
Evens, R., Uyar, A., & Majić, T. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_612 · Cited by 2
Acute psilocin increased cortical activity in rat
Liu, J., Wang, Y., Xia, K., Wu, J., Zheng, D., Cai, A., Yan, H., & Su, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1593703 · Cited by 3
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies
Farré‐Colomés, À., Rublinetska, O., & Soto-Angona, Ó. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00384-w · Cited by 2
Corolaires en neuro-imagerie des effets des psychédéliques classiques : une revue systématique de la littérature
Dost, D., Benyamina, A., & Karila, L. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.007 · Cited by 2
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 3
Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology
McGovern, H. T., Wellman, N., Hutchinson, B. T., Oestreich, L., Cooper, S., Fonzo, G. A., & Doss, M. K. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07163-z · Cited by 2
Mechanisms Linking Threat- and Deprivation-Related Childhood Adversity and Depression: The Biopsychosocial Model
Kemala, C. N., Jongsma, M. L. A., Hendrawan, D., & Becker, E. S. (2023) · Psychological Research on Urban Society · doi:10.7454/proust.v6i1.1105 · Cited by 2
Early and Contemporary Human Neuroimaging Studies of Serotonergic PsychedelicsPreprint
Tagliazucchi, E. (2020) · Preprints.org · doi:10.20944/preprints202005.0510.v1 · Cited by 1
Mindful Nonreactivity Moderates the Relationship between Posttraumatic Stress Disorder and Depression
Kaplan, J., Somohano, V. C., Eddy, A., Oken, B., & Wahbeh, H. (2022) · Journal of Loss and Trauma · doi:10.1080/15325024.2022.2030019 · Cited by 1
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121423 · Cited by 1
Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action
Kazdan, J., Ladha, K. S., & Husain, M. I. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70238 · Cited by 2
Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration
Effinger, D. P., Hoffman, J. L., Quadir, S. G., Rollison, C. S., Toedt, D., Sanchez, M. E., High, M. W., Hodge, C. W., & Herman, M. A. (2026) · Nature Communications · doi:10.1038/s41467-026-71481-1 · Cited by 1
Sex-dependent effects of psychedelics: review of evidence from rodent models
Marecki, R., Zaniewska, W., Hamed, A., Waszkiewicz, N., Baker, J. J., & Łukasiewicz, K. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1824073 · Cited by 1
Possível uso da Psilocibina no tratamento psiquiátrico, incluindo sequelas da COVID-19
Bonifácio, M. C. A. C., Bento, P. B. B., Trevisan, K., Cristina-Pereira, R., Magri, M. P. D. F., & Aversi‐Ferreira, T. A. (2021) · Research Society and Development · doi:10.33448/rsd-v10i11.19259 · Cited by 1
“Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential
An, Y., Park, S.-Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.243 · Cited by 1
Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-1 · Cited by 1
The role of psilocybin in depressive disorders
Najib, J. S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2396536 · Cited by 1
There’s More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression
Fonzo, G. A., Doss, M. K., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250247 · Cited by 1
Identification and management of anxious depression in patients with treatment-resistant depression
Hershenberg, R., Rapaport, M. H., & Weischedel, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00029-3 · Cited by 1
Cultivating Positive Health, Learning, and Community: The Return of Mesoamerica’s Quetzalcoatl and the Venus Star
Garcia, S. A., & Márquez, C. I. (2021) · Genealogy · doi:10.3390/genealogy5020053 · Cited by 1
P.0885 The effect of psilocybin therapy for depression on low-frequency brain activity in response to music
Wall, M. B., Lam, C., Ertl, N., Kaelen, M., Roseman, L., Nutt, D., & Carhart-Harris, R. L. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.741 · Cited by 1
Self-citation
Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical studyPreprint
Swanson, L. R., Jungers, S., Varghese, R., Cullen, K. R., Evans, M. D., Nielson, J. L., & Schallmo, M. (2024) · doi:10.31234/osf.io/5rm62 · Cited by 1
Everything old is new again: are psychedelic medicines poised to take mental health by storm?
Raison, C. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12975
THE EFFECTS OF LONG-TERM DIABETES MELLITUS ON ADULT NEUROGENESIS IN SUBVENTRICULAR ZONE OF THE RAT BRAIN
Boy, T. H. (2018)
5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology
Bahi, C. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.08429 · Cited by 1
The Psychological Processes of Classic Psychedelics in the Treatment of Depression: A Systematic Review ProtocolPreprint
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin‐Purcell, L., & Murray, G. (2020) · Research Square · doi:10.21203/rs.3.rs-121894/v1
Avaliação das possíveis interações entre o canabidiol e a ayahuasca em voluntários saudáveis: um estudo randomizado, duplo-cego e controlado com placebo
Rossi, G. N. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08022021-150020
Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?
Cotovio, G., Maia, A., Velosa, A., Seybert, C., & Oliveira-Maia, A. J. (2021) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.2021.v7.i3.241
Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controlsPreprint
Aharon-Almagor, A., & Barrett, F. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1529935/v1
Psilocybe mexicana R. Heim – Mexikanischer Kahlkopf
Kuhn, A., & Melzig, M. F. (2022) · Zeitschrift für Phytotherapie · doi:10.1055/a-1540-9907
P.609 Therapeutic mechanisms of psychedelic drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Mertens, L., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D., & Carhart-Harris, R. L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.593
Self-citation
A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed MindsPreprint
Carhart-Harris, R. L., Daws, R. E., & Nutt, D. J. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/pdbf5
Self-citation
Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on PsilocybinPreprint
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ztyxh
Application of psilocybin in mental health disorders
Chen, J. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/21/20230859
Exploring inner depths
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-2
THE CONNECTION BETWEEN THE INDIVIDUAL SUBJECTIVE WELL-BEING AND THE MYSTICAL EXPERIENCE PRODUCED BY THE USE OF PSYCHEDELICS
Kudrina, T., & Anna, K. (2023) · PSYCHOLOGICAL JOURNAL · doi:10.31108/1.2023.9.7.5
Psychedelics in psychiatry
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00015-x

Authors: Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L.
Affiliations: Imperial College London (GB)
Corresponding author: Roseman, Leor
ORCID: Roseman, Leor
Demetriou, Lysia
Wall, Matthew B.
Nutt, David J.
Carhart-Harris, Robin L.
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2018-11
Volume: 142
Pages: 263-269
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2017.12.041
OpenAlex: W2781340150
Cited by: 230
References: 57
Citations by year: 2026: 30 · 2025: 34 · 2024: 38 · 2023: 30 · 2022: 34 · 2021: 27 · 2020: 18 · 2019: 10 · 2018: 8
FWCI: 12.42
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Neuropharmacology (publishedVersion, cc-by)
PubMed (publishedVersion)
Spiral (Imperial College London) (submittedVersion, cc-by)
Funders: Imperial College Scholarship Scheme
Imanova
Edmund J Safra Foundation (P17264)
Alex Mosely Charitable Trust (G30444)
MRC clinical development scheme (MR/J00460X/1)
Alex Mosley Charitable Trust
COMPASS group (I30006)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: psilocybin, treatment-resistant depression, amygdala, emotional face processing, fearful faces, happy faces, psychological support, selective serotonin reuptake inhibitors, antidepressant mechanism, emotional responsiveness
MeSH terms: Facial Recognition, Adult, Amygdala, Antidepressive Agents, Brain Mapping, Combined Modality Therapy, Emotions, Female, Hallucinogens, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prognosis, Psilocybin, Psychotherapy, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks